In contrast to beneficial effects in IBD, SR3335 inhibited TNFα in TH17 and TH17.1 cells; inhibition of TNF signaling, via use of non-selective TNF inhibitors, exacerbated MS62,63 and induced new cases of demyelinating disease and neuropathies in patients treated for other inflammatory diseases64,65. This evidence concerns the gene TNF and inflammatory bowel disease.